Oncology

Perioperative chemoimmunotherapy improves survival and pathologic response in resectable NSCLC.

A systematic review of 16 studies (n=4646) found perioperative immunotherapy plus chemotherapy increased survival and pathological response versus chemotherapy alone. The pooled evidence consistently favored chemoimmunotherapy for these outcomes across heterogeneous trial designs. Studies variably reported adverse events, but the combination tended toward a higher risk of treatment-related adverse events. Heterogeneity in endpoints and study conduct limits precise magnitude estimates and warrants cautious interpretation. 1

Atypical EGFR and non‑G12C KRAS mutations are common in a diverse resected lung adenocarcinoma cohort.

In 292 resected lung adenocarcinomas, 40.8% were Black and 28.1% Hispanic, and EGFR positivity was independently associated with Hispanic ethnicity (aOR 3.88). Among EGFR-positive tumors, 26% were atypical, with higher numerical proportions in Black (37%) and Hispanic (27%) patients versus White (14%). KRAS mutations were predominantly non‑G12C (58%) and showed no racial/ethnic association. These findings highlight the need for comprehensive NGS and inclusive trial enrollment to avoid leaving underserved patients without targeted options. 2

Geographic and socioeconomic trial variables are rarely reported in US cancer RCTs.

Systematic review of 441 US randomized cancer trials found age and sex nearly universal, and race/ethnicity reporting rose from 62.3% (2020) to 93.9% (2025). No trials reported rurality, income, or area deprivation; only 2 reported education and 1 reported insurance. This sparse reporting prevents robust assessment of trial generalizability across socioeconomic and geographic subgroups. Clinicians and guideline panels should note this gap when applying trial results to diverse practice settings. 3